$GILD — X 투자자들은 지금 무슨 이야기를 하나

$GILD길리어드 사이언스 · Drug Manufacturers - General · 1829억 달러

$147.50

프리마켓+0.0%

이벤트 흐름

주요 이벤트 · 시간순

15건

2026-09-15 → 09-16기업호재
Gilead Expands PAHO Deal to 14 Latin American Countries영어 원문
Adds 14 countries to lenacapavir access strategy, broadening HIV prevention drug availability
첫날 -0.1% · 5일 후 +4.4%
전개 과정 2회
- 2026-09-15 Expands access to twice-yearly lenacapavir for PrEP across Latin America and the Caribbean
- 2026-09-16 Adds 14 countries to lenacapavir access strategy, broadening HIV prevention drug availability
2026-08-28 → 09-02제품호재
Gilead Raises 2026 HIV Sales Outlook After Bixlenvo Approval영어 원문
Post-FDA approval, Gilead lifts 2026 HIV sales growth outlook to 9%, signaling commercial confidence
첫날 -2.1% · 5일 후 +3.7%
전개 과정 2회
- 2026-08-28 FDA greenlights Bixlenvo for virologically suppressed adults with HIV, simplifying complex regimens
- 2026-09-02 Post-FDA approval, Gilead lifts 2026 HIV sales growth outlook to 9%, signaling commercial confidence

이전 이벤트 13건

2026-09-01애널리스트호재
Gilead Upgraded to Zacks Strong Buy영어 원문
Zacks upgrades GILD to Strong Buy on earnings optimism, reflecting analyst positivity
첫날 +2.4% · 5일 후 -2.8%
2026-08-29M&A·자금조달
GILD Sees Mixed Q2 Institutional Moves: Archer New Position, BNP Increases, Beacon Cuts영어 원문
Mixed institutional moves highlight divergent views on GILD
첫날 +0.5% · 5일 후 +0.2%
2026-08-28제품호재
GILD's Bixlenvo FDA Approval Expands Coverage to Complex Patients영어 원문
첫날 -2.1% · 5일 후 +3.7%
2026-08-26기업
GILD Executives to Present at Q3 2026 Investor Conferences영어 원문
Company announcement confirms executives will speak at Wells Fargo Healthcare Conference on Sept 9
첫날 -0.5% · 5일 후 +1.0%
2026-08-06실적
실적 발표영어 원문
Base business sales grew 10% year-over-year to $7.6 billion in Q2 2026, the strongest second-quarter growth in 3 years.
첫날 -0.7% · 5일 후 +5.6%
2026-08-05실적악재
Gilead Q2 Revenue Beat, Loss, Cuts FY Guidance영어 원문
Q2 product sales $7.6B up 10% YoY, driven by HIV and Trodelvy, but acquisition charges caused a loss; raised full-year product sales guidance.
첫날 -2.6% · 5일 후 +3.1%
전개 과정 2회
- 2026-08-05 Q2 revenue $7.8B beat, adj. EPS -$6.75, Veklury sales plunge, FY guidance lowered.
- 2026-08-05 Q2 product sales $7.6B up 10% YoY, driven by HIV and Trodelvy, but acquisition charges caused a loss; raised full-year product sales guidance.
2026-08-04실적
실적 발표영어 원문
Base business sales grew 10% year-over-year to $7.6 billion in Q2 2026, the strongest second-quarter growth in 3 years.
첫날 +3.1% · 5일 후 +0.4%
2026-08-048-K 공시
8-K: 실적 공시
첫날 +3.1% · 5일 후 +0.4%
2026-08-03실적
실적 발표영어 원문
Base business sales grew 10% year-over-year to $7.6 billion in Q2 2026, the strongest second-quarter growth in 3 years.
첫날 +0.7% · 5일 후 +1.5%
2026-08-01M&A·자금조달호재
Multiple Institutions Initiate or Add Gilead Positions in Q1영어 원문
Avidity bought 20k shares; Axiom initiated 4,858 shares, reflecting institutional moves
첫날 +0.7% · 5일 후 +1.5%
2026-07-21애널리스트악재
Leerink Partners: 투자의견 하향 → Market Perform
첫날 -2.2% · 5일 후 +3.1%
2026-07-20M&A·자금조달악재
Multiple Institutions Trim Gilead Sciences Holdings in Q1영어 원문
Boston Common, Dimensional, and Allspring disclosed reduced stakes in 13F filings, indicating institutional repositioning.
첫날 -0.8% · 5일 후 -2.0%
2026-07-06애널리스트호재
HSBC: 투자의견 상향 → Buy
첫날 -1.3% · 5일 후 +1.4%

①

강세 vs 약세

방향별 정리 · 원문 링크

호재 요인0

아직 항목이 없어요

리스크 요인0

아직 항목이 없어요

최근 2주간 X 신뢰 작성자 의견을 AI가 묶은 주장이며, 수치는 독립 작성자 수다. 언급량은 방향을 예측하지 않는다 · 투자 권유 아님

⑩

토론

첫 댓글을 남겨 보세요

서로 존중 · 의견은 작성자 본인 책임 · 투자 권유 아님

아직 댓글이 없어요.

사실과 의견을 구분해 표시 · 모든 항목 원문 확인 가능 · 본 정보는 투자 권유를 목적으로 하지 않으며, 투자 판단과 그 결과에 대한 책임은 투자자 본인에게 있습니다.

이벤트 흐름

주요 이벤트 · 시간순

15건

2026-09-15 → 09-16기업호재
Gilead Expands PAHO Deal to 14 Latin American Countries영어 원문
Adds 14 countries to lenacapavir access strategy, broadening HIV prevention drug availability
첫날 -0.1% · 5일 후 +4.4%
전개 과정 2회
- 2026-09-15 Expands access to twice-yearly lenacapavir for PrEP across Latin America and the Caribbean
- 2026-09-16 Adds 14 countries to lenacapavir access strategy, broadening HIV prevention drug availability
2026-08-28 → 09-02제품호재
Gilead Raises 2026 HIV Sales Outlook After Bixlenvo Approval영어 원문
Post-FDA approval, Gilead lifts 2026 HIV sales growth outlook to 9%, signaling commercial confidence
첫날 -2.1% · 5일 후 +3.7%
전개 과정 2회
- 2026-08-28 FDA greenlights Bixlenvo for virologically suppressed adults with HIV, simplifying complex regimens
- 2026-09-02 Post-FDA approval, Gilead lifts 2026 HIV sales growth outlook to 9%, signaling commercial confidence
2026-09-01애널리스트호재
Gilead Upgraded to Zacks Strong Buy영어 원문
Zacks upgrades GILD to Strong Buy on earnings optimism, reflecting analyst positivity
첫날 +2.4% · 5일 후 -2.8%
2026-08-29M&A·자금조달
GILD Sees Mixed Q2 Institutional Moves: Archer New Position, BNP Increases, Beacon Cuts영어 원문
Mixed institutional moves highlight divergent views on GILD
첫날 +0.5% · 5일 후 +0.2%
2026-08-28제품호재
GILD's Bixlenvo FDA Approval Expands Coverage to Complex Patients영어 원문
첫날 -2.1% · 5일 후 +3.7%

이전 이벤트 10건

2026-08-26기업
GILD Executives to Present at Q3 2026 Investor Conferences영어 원문
Company announcement confirms executives will speak at Wells Fargo Healthcare Conference on Sept 9
첫날 -0.5% · 5일 후 +1.0%
2026-08-06실적
실적 발표영어 원문
Base business sales grew 10% year-over-year to $7.6 billion in Q2 2026, the strongest second-quarter growth in 3 years.
첫날 -0.7% · 5일 후 +5.6%
2026-08-05실적악재
Gilead Q2 Revenue Beat, Loss, Cuts FY Guidance영어 원문
Q2 product sales $7.6B up 10% YoY, driven by HIV and Trodelvy, but acquisition charges caused a loss; raised full-year product sales guidance.
첫날 -2.6% · 5일 후 +3.1%
전개 과정 2회
- 2026-08-05 Q2 revenue $7.8B beat, adj. EPS -$6.75, Veklury sales plunge, FY guidance lowered.
- 2026-08-05 Q2 product sales $7.6B up 10% YoY, driven by HIV and Trodelvy, but acquisition charges caused a loss; raised full-year product sales guidance.
2026-08-04실적
실적 발표영어 원문
Base business sales grew 10% year-over-year to $7.6 billion in Q2 2026, the strongest second-quarter growth in 3 years.
첫날 +3.1% · 5일 후 +0.4%
2026-08-048-K 공시
8-K: 실적 공시
첫날 +3.1% · 5일 후 +0.4%
2026-08-03실적
실적 발표영어 원문
Base business sales grew 10% year-over-year to $7.6 billion in Q2 2026, the strongest second-quarter growth in 3 years.
첫날 +0.7% · 5일 후 +1.5%
2026-08-01M&A·자금조달호재
Multiple Institutions Initiate or Add Gilead Positions in Q1영어 원문
Avidity bought 20k shares; Axiom initiated 4,858 shares, reflecting institutional moves
첫날 +0.7% · 5일 후 +1.5%
2026-07-21애널리스트악재
Leerink Partners: 투자의견 하향 → Market Perform
첫날 -2.2% · 5일 후 +3.1%
2026-07-20M&A·자금조달악재
Multiple Institutions Trim Gilead Sciences Holdings in Q1영어 원문
Boston Common, Dimensional, and Allspring disclosed reduced stakes in 13F filings, indicating institutional repositioning.
첫날 -0.8% · 5일 후 -2.0%
2026-07-06애널리스트호재
HSBC: 투자의견 상향 → Buy
첫날 -1.3% · 5일 후 +1.4%

$GILD (길리어드 사이언스) — X 투자자 토론

5팩터 평가: 중간 등급 (섹터 내 백분위 35.9)

$GILD 종목을 가장 많이 언급한 신뢰 작성자

$GILD 종목이 등장한 최근 헤드라인

$GILD (길리어드 사이언스) — X 투자자 토론

5팩터 평가: 중간 등급 (섹터 내 백분위 35.9)

$GILD 종목을 가장 많이 언급한 신뢰 작성자

$GILD 종목이 등장한 최근 헤드라인

Gilead Expands PAHO Deal to 14 Latin American Countries영어 원문

Gilead Raises 2026 HIV Sales Outlook After Bixlenvo Approval영어 원문

Gilead Upgraded to Zacks Strong Buy영어 원문

GILD Sees Mixed Q2 Institutional Moves: Archer New Position, BNP Increases, Beacon Cuts영어 원문

GILD's Bixlenvo FDA Approval Expands Coverage to Complex Patients영어 원문

GILD Executives to Present at Q3 2026 Investor Conferences영어 원문

실적 발표영어 원문

Gilead Q2 Revenue Beat, Loss, Cuts FY Guidance영어 원문

실적 발표영어 원문

8-K: 실적 공시

실적 발표영어 원문

Multiple Institutions Initiate or Add Gilead Positions in Q1영어 원문

Leerink Partners: 투자의견 하향 → Market Perform

Multiple Institutions Trim Gilead Sciences Holdings in Q1영어 원문

HSBC: 투자의견 상향 → Buy

강세 vs 약세

토론

Gilead Expands PAHO Deal to 14 Latin American Countries영어 원문

Gilead Raises 2026 HIV Sales Outlook After Bixlenvo Approval영어 원문

Gilead Upgraded to Zacks Strong Buy영어 원문

GILD Sees Mixed Q2 Institutional Moves: Archer New Position, BNP Increases, Beacon Cuts영어 원문

GILD's Bixlenvo FDA Approval Expands Coverage to Complex Patients영어 원문

GILD Executives to Present at Q3 2026 Investor Conferences영어 원문

실적 발표영어 원문

Gilead Q2 Revenue Beat, Loss, Cuts FY Guidance영어 원문

실적 발표영어 원문

8-K: 실적 공시

실적 발표영어 원문

Multiple Institutions Initiate or Add Gilead Positions in Q1영어 원문

Leerink Partners: 투자의견 하향 → Market Perform

Multiple Institutions Trim Gilead Sciences Holdings in Q1영어 원문

HSBC: 투자의견 상향 → Buy